DE602004017479D1 - Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon - Google Patents
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davonInfo
- Publication number
- DE602004017479D1 DE602004017479D1 DE602004017479T DE602004017479T DE602004017479D1 DE 602004017479 D1 DE602004017479 D1 DE 602004017479D1 DE 602004017479 T DE602004017479 T DE 602004017479T DE 602004017479 T DE602004017479 T DE 602004017479T DE 602004017479 D1 DE602004017479 D1 DE 602004017479D1
- Authority
- DE
- Germany
- Prior art keywords
- sup
- thienopyridinphenylacetamides
- suited
- derivatives
- antiangiogenic agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49907703P | 2003-08-29 | 2003-08-29 | |
PCT/IB2004/002688 WO2005021554A1 (fr) | 2003-08-29 | 2004-08-16 | Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004017479D1 true DE602004017479D1 (de) | 2008-12-11 |
Family
ID=34272772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004017479T Active DE602004017479D1 (de) | 2003-08-29 | 2004-08-16 | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
Country Status (10)
Country | Link |
---|---|
US (1) | US7208500B2 (fr) |
EP (1) | EP1660504B1 (fr) |
JP (1) | JP2007504122A (fr) |
AT (1) | ATE412655T1 (fr) |
BR (1) | BRPI0413876A (fr) |
CA (1) | CA2536321A1 (fr) |
DE (1) | DE602004017479D1 (fr) |
ES (1) | ES2314444T3 (fr) |
MX (1) | MXPA06002296A (fr) |
WO (1) | WO2005021554A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5096142B2 (ja) | 2004-07-30 | 2012-12-12 | メチルジーン インコーポレイテッド | Vegfレセプターおよびhgfレセプターシグナル伝達の阻害剤 |
CN101072758B (zh) | 2004-10-12 | 2013-07-31 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
BRPI0610382A2 (pt) | 2005-05-20 | 2010-06-15 | Methylgene Inc | inibidores de sinalização de receptor de vegf e receptor de hgf |
CN101796055B (zh) | 2005-05-20 | 2013-09-04 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
AR059246A1 (es) * | 2006-01-30 | 2008-03-19 | Array Biopharma Inc | Compuestos heterobiciclicos de tiofeno y metodos de uso |
UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US20080064718A1 (en) * | 2006-03-22 | 2008-03-13 | Saavedra Oscar M | Inhibitors of protein tyrosine kinase activity |
US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
WO2007113565A1 (fr) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Dérivés de la naphtyridine comme agents anti-cancéreux |
WO2007113548A1 (fr) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Dérivés de naphtyridine |
WO2007134127A2 (fr) * | 2006-05-09 | 2007-11-22 | Board Of Regents, The University Of Texas System | Agents d'imagerie de l'apoptose |
WO2007146824A2 (fr) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinolines et méthodes d'utilisation |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
TWI438205B (zh) | 2008-03-05 | 2014-05-21 | Methylgene Inc | 蛋白質酪胺酸激酶活性抑制劑 |
MX2011004018A (es) * | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
GB0901835D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
GB0901834D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
EP2408300B1 (fr) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Dérivés d'ester d'amino, sels de ceux-ci et procédés d'utilisation |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
SG178963A1 (en) * | 2009-09-03 | 2012-04-27 | Allergan Inc | Compounds as tyrosine kinase modulators |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
WO2013044361A1 (fr) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Inhibiteurs de l'activité protéine tyrosine kinase |
WO2013044360A1 (fr) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Inhibiteurs de protéine tyrosine kinase |
US20130096135A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Selected Inhibitors of Protein Tyrosine Kinase Activity |
EP3293177A4 (fr) * | 2015-04-07 | 2018-12-12 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant |
WO2018156946A1 (fr) | 2017-02-24 | 2018-08-30 | Humanetics Corporation | Protection des tissus et atténuation des lésions causées par des événements ionisants induits par rayonnement |
US11129894B2 (en) * | 2017-09-29 | 2021-09-28 | - Humanetics Corporation | Sensitizing cells to proton radiation |
CN111825605B (zh) * | 2019-04-19 | 2023-03-31 | 中国科学院上海药物研究所 | 芳基酮酰胺类化合物及其制备方法和用途 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) * | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
AU686843B2 (en) | 1994-02-23 | 1998-02-12 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
CA2203517A1 (fr) | 1994-11-10 | 1996-05-23 | Alan M. Laibelman | Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
WO1996033172A1 (fr) * | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
ES2203642T3 (es) | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
WO1997034876A1 (fr) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Derives de cinnoline et leur emploi comme medicaments |
CA2258548C (fr) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives |
BR9709974A (pt) * | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
ES2191187T3 (es) | 1996-07-13 | 2003-09-01 | Glaxo Group Ltd | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa. |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
EP0923585B1 (fr) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Composes a base de phosphinate inhibiteurs des metalloproteases matricielles |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6548524B2 (en) * | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
CA2272705C (fr) | 1996-11-27 | 2003-03-18 | Pfizer Inc. | Derives de pyrimidines bicycliques fusionnes |
BR9714266A (pt) | 1997-01-06 | 2000-04-18 | Pfizer | Derivados de sulfona cìclicos. |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
AU722784B2 (en) | 1997-02-11 | 2000-08-10 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
EP1170017A1 (fr) | 1997-05-12 | 2002-01-09 | The Kennedy Institute Of Rheumatology | Utilisation du facteur de nécrose tumorale alpha (TNF-alpha) et du facteur de croissance des cellules endothéliales (VEGF) pour la préparation d'une composition thérapeutique |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
EP1005470B1 (fr) | 1997-08-22 | 2007-08-01 | AstraZeneca AB | Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese |
CA2303830A1 (fr) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Nouveaux inhibiteurs de l'angiogenese |
GB9722320D0 (en) * | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
CZ20001709A3 (cs) | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
AU2825899A (en) * | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
AU3850299A (en) | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
SK287132B6 (sk) | 1998-05-29 | 2009-12-07 | Sugen, Inc. | Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu |
AU4393199A (en) * | 1998-06-26 | 2000-01-17 | Takeda Chemical Industries Ltd. | Thienopyridine compounds, their production and use |
US6383744B1 (en) * | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
WO2000016781A1 (fr) | 1998-09-18 | 2000-03-30 | Smithkline Beecham Corporation | Inhibiteurs de la kinase chk1 |
BR9916536A (pt) | 1998-12-23 | 2002-01-02 | Searle & Co | Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
DE60038220T2 (de) | 1999-08-27 | 2009-03-12 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon |
EP1218494B1 (fr) | 1999-09-22 | 2005-04-06 | Canbas Co., Ltd. | Compositions et methodes d'inhibition de l'arret du cycle cellulaire g2 et de sensibilisation de cellules aux agents de degradation d'adn |
US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
JP2003527441A (ja) | 2000-03-22 | 2003-09-16 | グラクソ グループ リミテッド | 細胞周期を阻止する薬剤及び抗体を含む医薬 |
IL151992A0 (en) | 2000-03-31 | 2003-04-10 | Imclone Systems Inc | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
AU2001265953B2 (en) | 2000-05-12 | 2005-09-29 | D. Collen Research Foundation Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
AU2001296821A1 (en) | 2000-10-12 | 2002-04-22 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting angiogenesis using nadph oxidase inhibitors |
ATE369894T1 (de) | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
WO2002064170A1 (fr) | 2001-02-09 | 2002-08-22 | Children's Medical Center Corporation | Methode pour traiter le cancer et augmenter le taux d'hematocrite |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
WO2003000194A2 (fr) * | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux |
WO2003006059A1 (fr) | 2001-07-13 | 2003-01-23 | Imclone Systems Incorporated | Anticorps diriges contre vegfr-1 pour traiter le cancer du sein |
US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
DE60224299T2 (de) | 2001-10-25 | 2008-12-11 | Novartis Ag | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor |
-
2004
- 2004-08-16 AT AT04769139T patent/ATE412655T1/de not_active IP Right Cessation
- 2004-08-16 CA CA002536321A patent/CA2536321A1/fr not_active Abandoned
- 2004-08-16 DE DE602004017479T patent/DE602004017479D1/de active Active
- 2004-08-16 EP EP04769139A patent/EP1660504B1/fr not_active Not-in-force
- 2004-08-16 JP JP2006524445A patent/JP2007504122A/ja not_active Withdrawn
- 2004-08-16 MX MXPA06002296A patent/MXPA06002296A/es unknown
- 2004-08-16 WO PCT/IB2004/002688 patent/WO2005021554A1/fr active Application Filing
- 2004-08-16 BR BRPI0413876-7A patent/BRPI0413876A/pt not_active IP Right Cessation
- 2004-08-16 ES ES04769139T patent/ES2314444T3/es active Active
- 2004-08-26 US US10/928,674 patent/US7208500B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BRPI0413876A (pt) | 2006-10-24 |
ES2314444T3 (es) | 2009-03-16 |
US20050090509A1 (en) | 2005-04-28 |
CA2536321A1 (fr) | 2005-03-10 |
US7208500B2 (en) | 2007-04-24 |
JP2007504122A (ja) | 2007-03-01 |
ATE412655T1 (de) | 2008-11-15 |
WO2005021554A1 (fr) | 2005-03-10 |
EP1660504A1 (fr) | 2006-05-31 |
EP1660504B1 (fr) | 2008-10-29 |
MXPA06002296A (es) | 2006-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004017479D1 (de) | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
DE602005002562D1 (de) | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel | |
YU95102A (sh) | Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija | |
TR200102136T2 (tr) | Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler. | |
SG161217A1 (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | |
BRPI0414011A (pt) | naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos | |
WO2003074529A3 (fr) | Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation | |
DE60102171D1 (de) | Ketolidantibiotika | |
DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
DE602006017849D1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors | |
PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
DOP2003000595A (es) | Indolil-urea derivado de tienopiridinas utiles como agentes antiangionicos,y procedimientos para su uso | |
ECSP992984A (es) | Derivados de isotiazol utiles como agentes anticancerosos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |